A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants (clinicaltrials.gov) - Mar 7, 2026 - P1 | N=57 | Not yet recruiting | Sponsor: Endeavor Biomedicines, Inc.
New P1 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|